X-38411953-G-C
Variant summary
Our verdict is Pathogenic. The variant received 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_000531.6(OTC):c.959G>C(p.Arg320Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R320Q) has been classified as Uncertain significance.
Frequency
Consequence
NM_000531.6 missense
Scores
Clinical Significance
Conservation
Publications
- ornithine carbamoyltransferase deficiencyInheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P, Laboratory for Molecular Medicine, Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 13 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| OTC | NM_000531.6 | c.959G>C | p.Arg320Pro | missense_variant | Exon 9 of 10 | ENST00000039007.5 | NP_000522.3 | |
| OTC | NM_001407092.1 | c.959G>C | p.Arg320Pro | missense_variant | Exon 11 of 12 | NP_001394021.1 | ||
| OTC | XM_017029556.2 | c.*92G>C | downstream_gene_variant | XP_016885045.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Ornithine carbamoyltransferase deficiency Pathogenic:2
This variant disrupts the p.Arg320 amino acid residue in OTC. Other variant(s) that disrupt this residue have been observed in individuals with OTC-related conditions (PMID: 1671317), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. For these reasons, this variant has been classified as Pathogenic. This sequence change replaces arginine with proline at codon 320 of the OTC protein (p.Arg320Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is not present in population databases (ExAC no frequency). This variant has been observed to be de novo in an individual affected with OTC-related conditions (Invitae).
indicating that the boy is a Ornithine carbamoyltransferase deficiency patient. Parents and the boy underwent OTC gene testing simultaneously, and the results showed that the proband carried a hemizygous variant c.959G>C (Arg320Leu) in OTC gene, while the mother carried two compound heterozygous variants c.959G>C (Arg320Leu) and c.634G>A (Gly212Arg) in OTC gene .
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at